Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 10/20 | 0.50 |
| ▸ | MMP1 | P03956 | 9/20 | 0.50 |
| ▸ | MMP9 | P14780 | 7/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 3/20 | 0.46 |
| ▸ | MMP13 | P45452 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1909477 | 0.87 | GAA (0.58) | POLBGAAHPGDGRM3SMN1; SMN2 | |
| SCHEMBL2692091 | 0.84 | MMP13 (0.47) | MMP1MMP9MMP13EPHX2 | |
| SCHEMBL203227 | 0.84 | MMP13 (0.47) | MMP1MMP9MMP13EPHX2 | |
| SCHEMBL9903924 | 0.84 | MMP13 (0.47) | MMP1MMP9MMP13EPHX2 | |
| SCHEMBL1909368 | 0.80 | NPC1 (0.55) | HPGDSMN1; SMN2TSHRRECQL | |
| SCHEMBL2693341 | 0.80 | ALDH1A1 (0.49) | MMP9GAAHPGDSMN1; SMN2TSHR | |
| SCHEMBL2692903 | 0.79 | MMP13 (0.43) | MMP9SMN1; SMN2MMP13 | |
| SCHEMBL202818 | 0.79 | MMP13 (0.43) | MMP9SMN1; SMN2MMP13 | |
| SCHEMBL2693072 | 0.77 | MMP13 (0.45) | MMP3MMP1MMP9MMP7MMP13 | |
| SCHEMBL4650506 | 0.76 | PDK2 (0.39) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | MMP3 1396/4885MMP1 1000/4885MMP9 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.